CoChat
Sign Up
Cited by 281Asthma and respiratory diseasesIL-33, ST2, and ILC PathwaysAllergic Rhinitis and Sensitization

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma

Open access
Shimbara, Ayako, Christodoulopoulos, Pota, Soussi-Gounni, Abdelilah, Olivenstein, Ronald, Nakamura, Yutaka, Levitt, Roy C., Nicolaides, Nicholas C., Holroyd, Kenneth J., Tsicopoulos, Anne, Lafitte, Jean-Jacques, Wallaert, Benoit, Hamid, Qutayba A.·2000·Journal of Allergy and Clinical Immunology
DOI 10.1016/s0091-6749(00)90185-4
Open this paper in CoChat — free accountOpen PDF

Abstract

Background Bronchial asthma is a chronic inflammatory disease associated with genetic components. Recently IL-9 has been reported as a candidate gene for asthma and to be associated with bronchial hyperresponsiveness and elevated levels of total serum IgE. Objective To investigate the contribution of IL-9 to the pathogenesis of asthma, we examined the expression of IL-9 and its receptor (IL-9R) in bronchial tissue from subjects with atopic asthma (n = 10), chronic bronchitis (n = 11), and sarcoidosis (n = 9) and from atopic (n = 7) and nonatopic (n = 10) healthy control subjects. Methods Bronchial biopsy specimens were examined for the presence of IL-9 and IL-9R protein and messenger RNA (mRNA) by immunocytochemistry and in situ hybridization, respectively. To phenotype the cells expressing IL-9 in asthmatic tissue, combined in situ hybridization and immunocytochemistry was also performed. Results There was a highly significant difference (P <.001) in the expression of IL-9 mRNA in asthmatic airways (20.6 +/- 4.0 cells/mm of basement membrane) compared with chronic bronchitis (5.6 +/- 4.4), sarcoidosis (2.5 +/- 1.8), atopic control subjects (7.7 +/- 2.2), and healthy control subjects (2.7 +/- 2.3). The number of IL-9 immunoreactive cells was also greater in asthmatic patients compared with the other groups (P <.05). Although the level of IL-9R mRNA expression did not differ in any of the groups (P >.05), IL-9R immunoreactivity was significantly higher in asthmatic compared with control subjects. Furthermore, IL-9 mRNA expression levels were also significantly correlated with FEV(1) (P <.05) and the airway responsiveness to methacholine producing a 20% fall in FEV(1) (P <. 01). The cells expressing IL-9 mRNA in asthmatic tissue were CD3(+) lymphocytes (68%), major basic protein(+) eosinophils (16%), and elastase(+) neutrophils (8%). Conclusion The results of this study demonstrate the potential of IL-9 to be a marker for atopic asthma and furthermore suggest an important role for this cytokine in the pathophysiologic mechanisms of this disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0091-6749(00)90185-4

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Shimbara, A., Christodoulopoulos, P., Soussi-Gounni, A., Olivenstein, R., Nakamura, Y., Levitt, R. C., Nicolaides, N. C., Holroyd, K. J., Tsicopoulos, A., Lafitte, J.-J., Wallaert, B., & Hamid, Q. A.
Affiliations
  • McGill University (CA)
  • Inserm (FR)
ORCID
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2000-01
Volume
105
Issue
1
Pages
108-115
ISSN
0091-6749 (ISSN-L)
DOI
10.1016/s0091-6749(00)90185-4
OpenAlex
W2090021858
Cited by
281
References
38
Citations by year
2026: 1 · 2025: 7 · 2024: 8 · 2023: 3 · 2022: 9 · 2021: 11 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 12 · 2015: 17 · 2014: 7 · 2013: 15 · 2012: 16
FWCI
11.25
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Allergy and Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
Keywords
IL-9, IL-9 receptor, asthma, allergic asthma, chronic bronchitis, sarcoidosis, airway inflammation, eosinophils, neutrophils, CD3+ T cells, airway hyperresponsiveness, methacholine challenge, FEV1, candidate genes, cytokine expression, lung disease biomarkers
MeSH terms
Adult, Asthma, Bronchi, Bronchial Diseases, Bronchitis, Chronic Disease, Female, Humans, Hypersensitivity, Male, Reference Values, RNA, Messenger, Sarcoidosis, Interleukin-9, Receptors, Interleukin, Receptors, Interleukin-9

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review